Press about RVC

The RBV Capital Fund invested in the American Gene Therapy Technology Immusoft

According to the information analytical portal “Russian Venture — Telegram Analytics”, the RBV Capital Fund created with the participation of the RVC and R-Pharm invested in the Immusoft gene therapy technology.

Breakout Ventures, Alexandria Venture Investments, DEFTA Partners and Mesa Verde Venture Partners also participated in the round. In total, the companies invested $20 Mio.

Immusoft develops an immune cell technology that uses the blood cells of a patient to create therapeutic proteins for treatment of diseases.

This process is called the Immune System Programming, or ISP. The finances will be used to support the technology that, in its turn, is aimed at a new approach to the treatment of patients with Hurler syndrome by means of clinical research of phase I and II.